IL10 and graft versus host disease: Collectively, eMSCs-IL10 exhibit robust IL-10 secretion, exert immunosuppressive effects both in vitro and in vivo, and may provide a more effective therapy when used in the clinical management of GvHD without concerns of MSC maltransformation.